Intravesical Chemotherapy vs BCG for Bladder Cancer: Which Treatment Is Right for You?

After a TURBT (Transurethral Resection of Bladder Tumour), patients with non-muscle-invasive bladder cancer are often advised treatment directly inside the urinary bladder.

Two terms commonly encountered are intravesical chemotherapy and BCG therapy.

This understandably raises several questions:

Is BCG a type of chemotherapy? Which treatment is more effective? Why does one patient receive chemotherapy while another receives BCG? And does needing BCG mean that the cancer is more advanced?

The most important principle is that intravesical chemotherapy and BCG are different treatments with different roles. The choice is primarily determined by the risk category of the bladder cancer, rather than one treatment simply being “stronger” or “better” than the other.

What Is Non-Muscle-Invasive Bladder Cancer?

Bladder cancers that have not invaded the muscular wall of the bladder are collectively called non-muscle-invasive bladder cancer (NMIBC).

This includes:

• Ta: tumour confined to the inner lining of the bladder without invasion
• T1: tumour invading the connective tissue beneath the lining but not the bladder muscle
• Carcinoma in situ (CIS): a flat, high-grade cancer confined to the bladder lining

NMIBC accounts for a substantial proportion of newly diagnosed bladder cancers.

However, not all NMIBC behaves in the same way.

Some tumours have a relatively low risk of progression, whereas others—particularly high-grade T1 disease and CIS—have considerably greater potential to recur or progress.

This is why treatment after TURBT is based on risk stratification.

Why Is Treatment Given Inside the Bladder?

Both intravesical chemotherapy and BCG are administered directly into the bladder through a urinary catheter.

This is called intravesical therapy.

A catheter is temporarily passed through the urethra, the medication is instilled into the bladder, and the catheter is subsequently removed or managed according to the treatment protocol.

The objective is to expose the bladder lining directly to treatment while limiting unnecessary systemic exposure.

However, the mechanism of action differs significantly between chemotherapy and BCG.

What Is Intravesical Chemotherapy?

Intravesical chemotherapy involves placing an anticancer drug directly into the bladder.

Commonly used agents include:

• Mitomycin C
• Gemcitabine

Other intravesical chemotherapy regimens may be used depending upon the clinical situation, previous treatment and availability.

Unlike intravenous chemotherapy, which circulates throughout the body, intravesical chemotherapy primarily acts locally within the bladder.

Why Is Chemotherapy Sometimes Given Immediately After TURBT?

For appropriately selected patients, a single immediate instillation of intravesical chemotherapy after TURBT may reduce the risk of tumour recurrence.

This is particularly relevant in patients with tumours expected to fall into lower-risk categories.

The rationale is to destroy free-floating tumour cells and microscopic residual tumour cells that may remain after resection.

However, immediate instillation is not appropriate in every patient. It may be avoided when there is concern about bladder perforation, extensive resection, significant bleeding or other circumstances where drug leakage outside the bladder could be unsafe.

Is Intravesical Chemotherapy Only a Single Dose?

No.

There are two distinct situations.

Immediate postoperative chemotherapy

A single dose may be administered soon after TURBT in appropriately selected patients.

Induction or further intravesical chemotherapy

Patients with certain intermediate-risk or recurrent tumours may receive a course of intravesical chemotherapy over several weeks, with further treatment depending upon the individual risk profile and response.

Therefore, “intravesical chemotherapy” does not necessarily refer to one standard treatment schedule.

What Is BCG Treatment for Bladder Cancer?

BCG stands for Bacillus Calmette-Guérin.

Importantly:

BCG is not chemotherapy.

BCG is a form of intravesical immunotherapy.

It contains an attenuated form of Mycobacterium bovis. When placed inside the bladder, BCG stimulates a strong local immune response against bladder cancer cells.

BCG has been used for decades and remains a central treatment for appropriately selected patients with high-risk non-muscle-invasive bladder cancer.

Which Bladder Cancers Are Usually Treated With BCG?

BCG is particularly important in patients with high-risk NMIBC, including many patients with:

• High-grade T1 bladder cancer
• Carcinoma in situ
• Other high-risk or selected very-high-risk NMIBC where bladder preservation is being pursued

The exact recommendation depends upon the complete pathological and clinical risk assessment.

BCG is generally given as an induction course, followed by maintenance treatment when appropriate.

This is very different from the single immediate dose of chemotherapy that some patients receive after TURBT.

Intravesical Chemotherapy vs BCG: What Is the Main Difference?

The easiest way to understand the distinction is:

	Intravesical Chemotherapy	BCG
Type of treatment	Chemotherapy	Immunotherapy
Given directly into bladder	Yes	Yes
Common examples	Gemcitabine, Mitomycin C	BCG
Common role	Low/intermediate-risk disease depending on circumstances	Primarily high-risk NMIBC
May be given immediately after TURBT	Yes, in selected patients	No
Induction course possible	Yes	Yes
Maintenance treatment	May be used depending on regimen/risk	Important component of BCG treatment
Systemic chemotherapy	No	No

This table is intentionally simplified. Actual treatment depends upon the patient's complete risk category rather than one pathological feature alone.

Which Is Better: BCG or Intravesical Chemotherapy?

There is no universal answer.

The question should not simply be:

“Which treatment is stronger?”

A better question is:

“Which treatment is appropriate for the risk category of my bladder cancer?”

For a patient with a low-risk tumour, BCG would usually represent unnecessary treatment.

For many patients with intermediate-risk NMIBC, intravesical chemotherapy can be an appropriate treatment option, although BCG may also be considered depending upon recurrence and progression risk.

For high-risk NMIBC, BCG with an appropriate maintenance strategy remains an important bladder-preserving treatment.

Therefore, treatment needs to match the biology and risk of the tumour.

How Do Doctors Decide Whether I Need Chemotherapy or BCG?

Several features are considered after TURBT.

These include:

Tumour stage
Is the tumour Ta, T1 or CIS?

Tumour grade
Is it low grade or high grade?

Number of tumours
Was there one tumour or were multiple tumours present?

Tumour size
Larger tumours can carry different recurrence risks.

Previous recurrence
Is this the first tumour or has the bladder cancer returned?

Carcinoma in situ
The presence of CIS significantly influences risk assessment.

Previous intravesical treatment
Previous BCG or chemotherapy affects subsequent treatment choices.

Quality of the TURBT
Was the tumour completely resected, and was appropriate detrusor muscle available for pathological assessment where required?

These factors are combined to classify patients into appropriate NMIBC risk categories.

Does High-Grade T1 Bladder Cancer Always Mean BCG?

Not necessarily.

High-grade T1 bladder cancer requires particularly careful evaluation.

A repeat TURBT may be required to ensure accurate staging and assess for residual disease.

Once staging has been adequately established, BCG may be an appropriate bladder-preserving treatment for many patients.

However, some patients have features indicating very-high-risk disease, where the possibility of early radical cystectomy should also be discussed.

This is important because repeated intravesical treatment should not delay definitive treatment in a patient whose tumour biology indicates a substantial risk of progression.

What Is Carcinoma In Situ and Why Is BCG Important?

Carcinoma in situ (CIS) is a flat, high-grade form of urothelial cancer.

Unlike a papillary bladder tumour, CIS may not form a prominent growth projecting into the bladder.

Although it remains confined to the bladder lining, CIS is biologically aggressive and carries a meaningful risk of progression.

BCG is an important treatment for CIS when bladder preservation is appropriate.

Patients require careful surveillance because response to treatment has important implications for subsequent management.

What Are the Side Effects of Intravesical Chemotherapy?

Because chemotherapy is administered directly into the bladder, systemic side effects are generally much less prominent than with intravenous chemotherapy.

Possible symptoms include:

• Burning during urination
• Increased urinary frequency
• Urgency
• Bladder discomfort
• Blood in the urine
• Chemical cystitis

The precise side-effect profile varies according to the drug and treatment schedule.

What Are the Side Effects of BCG?

BCG deliberately stimulates an immune response inside the bladder.

Patients may therefore experience:

• Burning during urination
• Frequency and urgency
• Bladder discomfort
• Blood in the urine
• Fever or flu-like symptoms
• General fatigue or malaise

Mild urinary symptoms for a limited period after treatment are relatively common.

However, persistent high fever or significant systemic illness after BCG requires prompt medical assessment, because serious BCG-related infection, although uncommon, can occur.

Patients receiving BCG should therefore be clearly informed about which symptoms are expected and which require urgent attention.

What Happens If Bladder Cancer Returns After BCG?

Recurrence after BCG does not have one universal meaning.

The next treatment depends on:

• Whether the recurrence is low or high grade
• Whether CIS is present
• How much BCG was previously received
• When the recurrence occurred
• Whether the tumour meets criteria for BCG-unresponsive disease
• The patient's overall fitness and preferences

This distinction is extremely important.

Simply repeating BCG indefinitely is not appropriate for every recurrence.

What Does “BCG-Unresponsive Bladder Cancer” Mean?

BCG-unresponsive NMIBC refers to specific patterns of persistent or recurrent high-grade disease despite adequate BCG treatment.

This terminology identifies a group of patients who are unlikely to obtain meaningful benefit from simply receiving additional BCG.

For suitable patients with high-risk BCG-unresponsive disease, radical cystectomy is an important standard treatment option.

For patients who are unwilling or medically unsuitable for cystectomy, other bladder-preserving treatments may be considered depending upon availability, tumour characteristics and contemporary treatment recommendations.

This is why identifying true BCG-unresponsive disease is much more important than simply saying:

“The BCG did not work.”

Can Intravesical Chemotherapy Be Used After BCG Failure?

In selected patients, alternative intravesical treatment strategies can be considered after previous BCG.

One increasingly used approach involves sequential intravesical gemcitabine and docetaxel, particularly in circumstances where further bladder-preserving treatment is being considered.

However, the availability of another intravesical treatment should not automatically mean that radical cystectomy should be postponed.

In patients with aggressive high-risk disease, the oncological risk of delaying definitive surgery must be considered carefully.

Does Receiving BCG Mean My Cancer Is Advanced?

Not necessarily.

This is a common misconception.

BCG is predominantly used for non-muscle-invasive bladder cancer—meaning the tumour has not invaded the detrusor muscle.

However, it is generally used when the biological characteristics of the NMIBC indicate a meaningful risk of recurrence or progression.

Therefore:

BCG treatment does not necessarily mean advanced bladder cancer.

It usually means that the tumour requires additional treatment beyond TURBT to reduce the risk of recurrence and progression.

Does Intravesical Treatment Replace TURBT?

No.

For most patients with papillary NMIBC, appropriate TURBT remains fundamental for removing visible tumour and establishing pathological stage and grade.

Intravesical therapy is generally an additional treatment after adequate tumour resection, rather than a substitute for appropriate TURBT.

This is why the quality of the initial TURBT and correct interpretation of the pathology report are so important.

Why Is Follow-Up Necessary After BCG or Chemotherapy?

Neither BCG nor intravesical chemotherapy eliminates the need for surveillance.

Bladder cancer has a recognised tendency to recur.

Follow-up may include:

• Cystoscopy
• Urine cytology in appropriate patients
• Imaging when indicated
• Repeat biopsy or TURBT when abnormalities are identified

The intensity of surveillance depends upon the patient's risk category.

High-risk patients generally require particularly careful long-term follow-up.

Intravesical Chemotherapy and BCG Treatment for Bladder Cancer in Lucknow

For patients diagnosed with non-muscle-invasive bladder cancer after TURBT, the next step should be determined by the complete pathological risk profile rather than simply choosing between two medications.

At Uro-Onco Connect, Lucknow, assessment of NMIBC focuses on:

TURBT quality → pathology review → Ta/T1/CIS staging → tumour grade → recurrence and progression risk → need for repeat TURBT → intravesical chemotherapy or BCG → surveillance → identification of treatment failure when present.

Patients with high-risk or recurrent disease also need timely identification of situations where continued intravesical therapy may no longer represent the most appropriate oncological strategy and radical cystectomy should be considered.

The objective is therefore not to determine whether BCG or chemotherapy is universally better.

The objective is to select the appropriate treatment for the individual patient's bladder cancer risk.

About Dr. Anshuman Singh

Dr. Anshuman Singh
M.S., M.Ch. Urology (Gold Medalist)
Fellowship – Uro-Oncology & Robotic Surgery (USI, Intuitive Certified)
Visiting Fellow – Robotic Uro-Oncology (Fundació Puigvert, Spain)
Clinical Observer – Robotic Pelvic Oncology (University College London Hospitals, London)

Vice Chairperson – Uro-Oncology & Robotic Surgery
Chandan Cancer Institute, Chandan Hospital
Lucknow

Dr. Anshuman Singh is a Uro-Oncology and Robotic Surgery specialist in Lucknow with dedicated training in the management of urological cancers. His clinical practice focuses on bladder cancer, prostate cancer, kidney cancer, testicular cancer, penile cancer and other complex urological malignancies, with particular emphasis on uro-oncological and robot-assisted surgery.

Patients diagnosed with non-muscle-invasive bladder cancer, recurrent bladder cancer, high-grade T1 disease, carcinoma in situ or recurrence following BCG can seek specialist uro-oncology consultation regarding risk assessment, intravesical treatment, surveillance and the appropriate timing of radical cystectomy when required.